Announcements
- Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
- Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
- Vivoryon Therapeutics N.V. Announces Changes to Board Composition
- Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
- Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
- Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
- Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023
- Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
- Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision
- Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose
More ▼
Key statistics
On Thursday, Vivoryon Therapeutics NV (0R3M:LSE) closed at 0.82, 99.99% above the 52 week low of 0.41 set on Apr 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 0.82 |
Average volume | 19.83k |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 20 minutes, as of Apr 25 2024 17:11 BST.
More ▼